MAZE
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) has 5 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 2, 2026.
Insiders have net sold $1.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jason Coloma
- Employees:141
- HQ:South San Francisco, CA, US
- IPO:2025-01-31
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.5M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$1.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Coloma Jason VFirst filing | Chief Executive Officer | Sale | 34,501 | $1.0M | Jul 2 | SEC ↗ |
Bernstein HaroldFirst in 3 months | President, R&D & CMO | Sale | 14,609 | $437K | Jul 2 | SEC ↗ |
Bernstein HaroldFirst filing | President, R&D & CMO | Sale | 15,000 | $442K | Apr 2 | SEC ↗ |
Bachrodt AmyFirst filing | SVP, Finance | Sale | 10,000 | $406K | Dec 31 | SEC ↗ |
Bachrodt AmyFirst filing | SVP, Finance | Sale | 5,000 | $200K | Dec 31 | SEC ↗ |
Dandekar AtulFirst filing | CSBO | Sale | 72,400 | $2.9M | Dec 31 | SEC ↗ |
Dandekar AtulFirst filing | CSBO | Sale | 100 | $4K | Dec 31 | SEC ↗ |
Related companies
Maze Therapeutics, Inc. is in the Healthcare sector.